thanks so much for your objective review. you are a bit of a god-send in that way.
My high level understanding is this . . .
to date, we have mutiple results from phase II tests that are very positive, applying the technology/medicine across multiple treatment possibilities, while acknowledging each treatment has its own best practice niche.
But when we focus in on phase III tests, we are reaching a critical focus point of the best application of the technology. So when results from phase III come in, we really have an idea of where we are in terms of rewards for the blessed reasearcher's time and investments have taken us. We have also reached that point where federal agencies consider approving the technology's use for widespread application.
That is when the rewards truly come to all those contributors and the patients have renewed hope for survival.
I find ONCY's entry into contractual obligations to produce the reo-virus on a commercial scale to be positively specculative as well.
Is that condensed version appropriate?
News 
Market Data 
Discover 
